In contrast, treatment with the same scFv A1 antibody resulted in BCR recognition on the surface of anti-C1q-specific B-cells and had a disease progression effect, enhancing lupus symptoms in the MRL/lpr mouse model of SLE. Here, BCR is linked to systemic lupus erythematosus.